Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial

被引：0

作者：

Christine Lundgren

Julia Tutzauer

Sarah E. Church

Olle Stål

Maria Ekholm

Carina Forsare

Bo Nordenskjöld

Mårten Fernö

Pär-Ola Bendahl

Lisa Rydén

机构：

[1] Region Jönköping County,Department of Oncology

[2] Linköping University,Department of Biomedical and Clinical Sciences

[3] Lund University,Division of Oncology, Department of Clinical Sciences Lund

[4] NanoString Technologies,Division of Surgery, Department of Clinical Sciences Lund

[5] Inc.,Department of Surgery

[6] Lund University,undefined

[7] Skåne University Hospital,undefined

来源：

Breast Cancer Research | / 25卷

关键词：

Gene expression signatures; Premenopausal; Tamoxifen; Prognostic; Predictive;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[41] RANDOMIZED ADJUVANT TRIAL TO EVALUATE THE ADDITION OF TAMOXIFEN AND PSK TO CHEMOTHERAPY IN PATIENTS WITH PRIMARY BREAST-CANCER - 5-YEAR RESULTS FROM THE NISHI-NIPPON GROUP OF THE ADJUVANT CHEMOENDOCRINE THERAPY FOR BREAST-CANCER ORGANIZATION
TOI, M
HATTORI, T
AKAGI, M
INOKUCHI, K
ORITA, K
SUGIMACHI, K
DOHI, K
NOMURA, Y
MONDEN, Y
HAMADA, Y
MORIMOTO, T
OGAWA, N
CANCER, 1992, 70 (10) : 2475 - 2483
[42] Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial
I Sestak
R Kealy
M Nikoloff
M Fontecha
J F Forbes
A Howell
J Cuzick
British Journal of Cancer, 2012, 107 : 230 - 233
[43] Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial
Sestak, I.
Kealy, R.
Nikoloff, M.
Fontecha, M.
Forbes, J. F.
Howell, A.
Cuzick, J.
BRITISH JOURNAL OF CANCER, 2012, 107 (02) : 230 - 233
[44] Relationship between the prognostic and predictive value of the intrinsic subtypes and a validated gene profile predictive of loco-regional control and benefit from post-mastectomy radiotherapy in patients with high-risk breast cancer
Tramm, Trine
Kyndi, Marianne
Myhre, Simen
Nord, Silje
Alsner, Jan
Sorensen, Flemming Brandt
Sorlie, Therese
Overgaard, Jens
ACTA ONCOLOGICA, 2014, 53 (10) : 1337 - 1346
[45] 2ND LINE AND 3RD LINE HORMONOTHERAPY IN ADVANCED POSTMENOPAUSAL BREAST-CANCER - A MULTICENTER RANDOMIZED TRIAL COMPARING MEDROXYPROGESTERONE ACETATE WITH AMINOGLUTETHIMIDE IN PATIENTS WHO HAVE BECOME RESISTANT TO TAMOXIFEN
GARCIAGIRALT, E
AYME, Y
CARTON, M
DABAN, A
DELOZIER, T
FARGEOT, P
FUMOLEAU, P
GORINS, A
GUERIN, D
GUERIN, R
MAILLART, P
MAURIAC, L
MAYLEVIN, F
METZ, R
NAMER, M
OLIVIER, JP
POMMATAU, E
POUILLART, P
PUJADELAURAINE, E
ROUESSE, J
SERROU, B
VITSE, M
ZYLBERAIT, D
BREAST CANCER RESEARCH AND TREATMENT, 1992, 24 (02) : 139 - 145
[46] Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial
Kyvernitakis, Ioannis
Kann, Peter Herbert
Thomasius, Friederike
Hars, Olaf
Hadji, Peyman
BONE, 2018, 114 : 109 - 115
[47] Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials
Regan, Meredith M.
Pagani, Olivia
Francis, Prudence A.
Fleming, Gini F.
Walley, Barbara A.
Kammler, Roswitha
Dell'Orto, Patrizia
Russo, Leila
Szoke, Janos
Doimi, Franco
Villani, Laura
Pizzolitto, Stefano
Oehlschlegel, Christian
Sessa, Fausto
Peg Camara, Vicente
Rodriguez Peralto, Jose Luis
MacGrogan, Gaetan
Colleoni, Marco
Goldhirsch, Aron
Price, Karen N.
Coates, Alan S.
Gelber, Richard D.
Viale, Giuseppe
BREAST CANCER RESEARCH AND TREATMENT, 2015, 154 (02) : 275 - 286
[48] Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials
Meredith M. Regan
Olivia Pagani
Prudence A. Francis
Gini F. Fleming
Barbara A. Walley
Roswitha Kammler
Patrizia Dell’Orto
Leila Russo
János Szőke
Franco Doimi
Laura Villani
Stefano Pizzolitto
Christian Öhlschlegel
Fausto Sessa
Vicente Peg Cámara
José Luis Rodríguez Peralto
Gaëtan MacGrogan
Marco Colleoni
Aron Goldhirsch
Karen N. Price
Alan S. Coates
Richard D. Gelber
Giuseppe Viale
Breast Cancer Research and Treatment, 2015, 154 : 275 - 286
[49] Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial
Aihara, Tomohiko
Yokota, Isao
Hozumi, Yasuo
Aogi, Kenjiro
Iwata, Hiroji
Tamura, Motoshi
Fukuuchi, Atsushi
Makino, Haruhiko
Kim, Ryungsa
Andoh, Masashi
Tsugawa, Koichiro
Ohno, Shinji
Yamaguchi, Takuhiro
Ohashi, Yasuo
Watanabe, Toru
Takatsuka, Yuichi
Mukai, Hirofumi
BREAST CANCER RESEARCH AND TREATMENT, 2014, 148 (02) : 337 - 343
[50] Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial
Tomohiko Aihara
Isao Yokota
Yasuo Hozumi
Kenjiro Aogi
Hiroji Iwata
Motoshi Tamura
Atsushi Fukuuchi
Haruhiko Makino
Ryungsa Kim
Masashi Andoh
Koichiro Tsugawa
Shinji Ohno
Takuhiro Yamaguchi
Yasuo Ohashi
Toru Watanabe
Yuichi Takatsuka
Hirofumi Mukai
Breast Cancer Research and Treatment, 2014, 148 : 337 - 343

← 1 2 3 4 5 →